Indacaterol
Top View
- CDR Pharmacoeconomic Review Report for Trelegy Ellipta
- Safety, Tolerability and Efficacy of Indacaterol, A
- A Real-World Evaluation of Indacaterol and Other Bronchodilators in COPD: the INFLOW Study
- Attachment: Product Information: Indacaterol Maleate/ Glycopyrronium Bromide
- Efficacy of a New Once-Daily Long-Acting Inhaled B2-Agonist Indacaterol Versus Twice-Daily Formoterol in COPD
- TRELEGY ELLIPTA (Fluticasone Furoate, Umeclidinium, and Vilanterol Changes Occur, Consider Appropriate Therapy
- Respiratory Beta-Agonists
- Anoro, INN-Umeclidinium Bromide/Vilanterol
- Rapid Simultaneous Determination of Indacaterol Maleate And
- Glycopyrronium/Mometasone Furoate Compared with Salmeterol
- Prohibited List 2021
- Duaklir Genuair INN-Aclidinium Bromide/Formoterol Fumarate
- FLAME: Indacaterol+Glycopyrronium Versus Salmeterol+Fluticasone for COPD 1
- Study Protocol of a Systematic Evidence Update by The
- Blinded 12-Week Comparison of Once-Daily Indacaterol and Tiotropium in COPD
- Trelegy Ellipta (Fluticasone Furoate/Umeclidinium/Vilanterol)
- Indacaterol Maleate / Glycopyrronium Bromide)
- Indacaterol, a Novel Once Daily Inhaled Β2-Adrenoreceptor Agonist